Advertisement

Pharmacy World and Science

, Volume 19, Issue 2, pp 73–81 | Cite as

Pharmacoeconomics: where is the link with pharmacokinetics and biopharmaceutics?

  • Frank Peys
Article

Abstract

Several, mainly macroeconomic factors are putting increasing pressure on health care budgets. These budget constraints lead to cost containment measures by all partners involved in health care. Pharmacotherapy, too, is facing an increasing involvement in health economics or outcomes research. This paper will first deal with some basic principles of pharmacoeconomics. The relationship with pharmacokinetics and biopharmaceutics has perhaps not yet been an issue as such, though it should be pointed out that they play a key role in the efficiency of drug use. Many of the basic R&D investments aimed at developing cost‐effective medicines should be founded on adequate pharmacokinetics. Also a rational use of drugs in practice can be achieved by adequate drug monitoring, resulting in a gain in cost‐effectiveness. Last but not least, pharmacokinetics and biopharmaceutics can offer opportunities for the rational use of new or existing pharmaceutical products and for the maintenance of a sufficient market share. Some of these more technical aspects are discussed in the second part of this presentation.

Cost‐effectiveness Pharmaceuticals Pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vertino JS Jr, Rodvold KA, Destache CJ. Cost Considerations in therapeutic drug monitoring of aminoglycosides. Clin Pharmacokinet. 1994;25(1):71.Google Scholar
  2. 2.
    Besarab A, Flaharty KK, Erslev AJ, McCrea JB, Vlasses PH, Medina F, Caro J, Morris E. Clinical Pharmacology and econom ics of recombinant human erythropoietin in endstage renal disease (S.C. administration). J Am Soc Nephro l 1992;2 (9):1405.Google Scholar
  3. 3.
    Bootman JL. 2 Presentations at the 24th Eur. Symp. on Clinical Pharmacy (Prague 10‐13 Oct. 1995), in Suppl. PWS., 17(5); 22 Sept. 1995.Google Scholar
  4. 4.
    Cramer MP, Saks SR. Translating Safety, Efficacy and Compliance into Economic Value for CR dosage forms. Pharmacoeconomics 1994;5(6):482.Google Scholar
  5. 5.
    Daumesnil R. Marketing considerations for oral CR dosage forms. 1st Int. Conference Berlin (G) 6 April 1992.Google Scholar
  6. 6.
    Destache CJ. Use of therapeutic drug monitoring in pharma‐coeconomics. Ther. Drug Monitoring 1993;15:608.Google Scholar
  7. 7.
    Dominguez GA. Contribution of biopharmaceutics and phar macokineticso improve drug therapy. Eur J Drug Metab–Pharmacokinet 1993;18(1).Google Scholar
  8. 8.
    Fenner H. Non‐steroidal anti‐inflammatory drugs: benefit‐risk evaluation in rheumatic diseases. J Rheumatol–Suppl. 1992; 32:98‐99.Google Scholar
  9. 9.
    Feuerstein J, Thomae R. Economic aspects of therapeutic drug monitoring. Wien Klin. Wochenschr.–Suppl. 1992; 191:85‐87.Google Scholar
  10. 10.
    Freston JW. Clinical significance of hypergastrinaemia: rele vance to gastrin monitoring during omeprazole therapy. Digestion 1992; 51–Suppl. 1:102‐114.Google Scholar
  11. 11.
    Frost JJ. The availability and accessibility of the contraceptive implant from family planning agencies in the United States. Fam Plann Perspect 1994;26(1):4.Google Scholar
  12. 12.
    Gorodischer R, Burtin P, Hwang P, Levine M, Koren G. Saliva versus blood sampling for therapeutic drug monitoring in chil dren: an economic analysis. Ther Drug Monit 1994; 16(5):437.Google Scholar
  13. 13.
    Jamali F. Stereo chemistry and bioequivalence. J Clinical Pharmacol 1992;32(10):930.Google Scholar
  14. 14.
    Kent DL, Vermes D, McDonnell M, Henikoff J, Fihn SD. A model for planning; optimal follow‐up for outpatients on warfarin anticoagulation. Med Decis Making 1992;12(2):132.Google Scholar
  15. 15.
    Kraus DM, Calligaro IL, Hatoum, HT. Multilevel model to assess appropriateness of pediatric serum drug concentrations. Am J Dis Child 1991;145(10):1171.Google Scholar
  16. 16.
    Marzo A, Balant JP. Bioequivalence for interchangeable multi‐source pharmaceutical products. Arzneimittelforschung 1995; 45(2):109.Google Scholar
  17. 17.
    Matzuk MM, Schlomchik M, Shaw LM. Making digoxin thera peutic drug monitoring more effective. Ther Drug Monit 1991;13(3):215.Google Scholar
  18. 18.
    Neu HC. Pharmacokinetics and costs of fluoroquinolone anti‐microbial agents. Am J Med 1992;92(4A):2S.Google Scholar
  19. 19.
    Nishioka FY. Prostaglandin E2 preparations for pre induction cervical ripening. J Reprod Med 1993;38(1 suppl.):83.Google Scholar
  20. 20.
    Paladino JA, Sperry HE, Backes JM, Gelber JA, Serrianne DJ, Cumbo TJ, Schentag JJ. Clinical and economic evaluation of oral ciprofloxacin after IV antibiotics. Am J Med 1991;91(5):462.Google Scholar
  21. 21.
    Parker ShE, Davey PG. Once‐daily aminoglycoside administra tion. Pharmacoeconomics 1995;7(5):393.Google Scholar
  22. 22.
    Peys F, Belg. Inst. Health Economics. Databank, update 1995.Google Scholar
  23. 23.
    Phrashker MJ, Meenan RF. The total costs of drug therapy for rheumatoid arthritis. Arthritis‐Rheum. 1995;38(3):318.Google Scholar
  24. 24.
    Roh JP, Yoshikawa TT. The cost of inappropriate use of anti‐infective agents in older patients. Drugs and Aging 1995; 6:263.Google Scholar
  25. 25.
    Shaw LM, Bonner HS, Fields L, Lieberman R. The use of concen tration measurements of parent drug and metabolites. Ther Drug Monit 1993;15:483.Google Scholar
  26. 26.
    Urquhart J. Role of patient compliance in clinical pharmacoki netics. Clin Pharmacokinet 1994;27(3):202.Google Scholar
  27. 27.
    Ushakov IuV, Kostiukova EG, Kudriakova TB. An economic eval uation in the pharmacokinetic prediction of preventive carba mazepine therapy. Zh‐Nevropatol Psikhiatr 1991;91(3):94.Google Scholar
  28. 28.
    Weiskopf RB, Eger EL. Comparing the costs of inhaled anesthet ics. Anesthesiology 1993;79(6):1413.Google Scholar
  29. 29.
    Whipple JK, Ausman RK, Franson T, Quebbeman EJ. Effect of individualized pharmacokinetic dosing on patient outcomes for aminoglycosides. Crit Care Med 1991;19(12):1480.Google Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Frank Peys
    • 1
  1. 1.Belgian Institute of Health EconomicsBrusselsBelgium

Personalised recommendations